Trial Profile
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe, Recalcitrant, Plaque Type Psoriasis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2012
Price :
$35
*
At a glance
- Drugs Lestaurtinib (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 28 Aug 2012 New trial record